Inhibition of HIV-1 by Lentiviral Vector-transduced SiRNAs in T Lymphocytes Differentiated in SCID-hu Mice and CD34+ Progenitor Cell-derived Macrophages
Overview
Pharmacology
Authors
Affiliations
The phenomenon of RNA interference mediated by small interfering RNAs (siRNAs) is a potent gene-silencing mechanism. A number of recent studies demonstrated inhibition of HIV-1 replication in cultured cells using this approach. To make further progress and harness this technology for HIV-1 gene therapy in a stem cell setting, in vivo studies using primary hematopoietic cells are needed. Using an HIV-based lentiviral vector we introduced an anti-Rev siRNA construct into CD34(+) hematopoietic progenitor cells. The siRNA-transduced progenitor cells were allowed to mature into macrophages in vitro and T cells in vivo in SCID-hu mouse thy/liv grafts. Phenotypically normal T cells and macrophages displaying characteristic surface markers were obtained. In vitro HIV-1 challenge of the siRNA-expressing macrophages and T cells with macrophage-tropic and T-cell-tropic HIV-1, respectively, showed marked viral resistance. These experiments demonstrate the utility of siRNAs delivered into hematopoietic stem cells via lentiviral vectors for future in vivo applications.
Optimal delivery of RNA interference by viral vectors for cancer therapy.
Wong B, Birtch R, Rezaei R, Jamieson T, Crupi M, Diallo J Mol Ther. 2023; 31(11):3127-3145.
PMID: 37735876 PMC: 10638062. DOI: 10.1016/j.ymthe.2023.09.012.
RNA Therapeutics for Improving CAR T-cell Safety and Efficacy.
Schaible P, Bethge W, Lengerke C, Haraszti R Cancer Res. 2022; 83(3):354-362.
PMID: 36512627 PMC: 7614194. DOI: 10.1158/0008-5472.CAN-22-2155.
Pai S, Mudgal J, Kamath B, Pai K Pharmacol Rep. 2021; 73(5):1265-1272.
PMID: 33840054 PMC: 8460518. DOI: 10.1007/s43440-021-00257-9.
Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA.
Abdul Ghafoor Raja M, Katas H, Amjad M Asian J Pharm Sci. 2020; 14(5):497-510.
PMID: 32104477 PMC: 7032099. DOI: 10.1016/j.ajps.2018.12.005.
Tsukamoto T Pharmaceutics. 2019; 11(3).
PMID: 30862061 PMC: 6470728. DOI: 10.3390/pharmaceutics11030114.